Injectable peptides are rapidly gaining popularity among consumers seeking benefits tied to weight loss, anti-aging, muscle recovery, and overall wellness, but growing demand is outpacing regulatory oversight and public understanding of the risks involved. There is an expanding gray-market peptide industry, where consumers are purchasing “research-grade” peptides online, often from overseas vendors, and self-administering injectable compounds without physician supervision or FDA approval.
There is increased public attention following comments from Robert F. Kennedy Jr. supporting expanded access to certain peptide products, while medical experts continue to raise concerns regarding safety, dosing, and product quality.
In an article by The Hill, Edgar J. Asebey provided insight into the regulatory and legal concerns surrounding the peptide marketplace. Asebey explained that many of the products being marketed online exist outside traditional FDA approval pathways and may constitute unapproved drugs under federal law.
“Most of these are not approved drugs. They are substances, chemicals, bioactive chemicals that have been studied, but not in human clinical trials, generally speaking. And so, from the FDA regulatory world, that’s called an unapproved drug.”
